Fosaprepitant
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Fosaprepitant
- Fosaprepitant: From Chemotherapy-Induced Nausea/Vomiting to Nephrogenic Syndrome of Inappropriate Antidiuresis
Fosaprepitant: From Chemotherapy-Induced Nausea/Vomiting to Nephrogenic Syndrome of Inappropriate Antidiuresis
One-Sentence Summary
Fosaprepitant is the intravenous prodrug of aprepitant, an NK1 (Substance P) receptor antagonist historically used for chemotherapy-induced nausea and vomiting (CINV) prevention. The TxGNN model’s top-ranked prediction for this drug is Nephrogenic Syndrome of Inappropriate Antidiuresis (NSIAD), but this candidate currently has no supporting clinical trials, no supporting literature, and no established mechanistic link — it is a model-only signal.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Chemotherapy-induced nausea and vomiting (CINV) prevention — not formally authorized in this jurisdiction (0 licenses on file) |
| Predicted New Indication | Nephrogenic Syndrome of Inappropriate Antidiuresis (NSIAD) |
| TxGNN Prediction Score | 99.92% (rank 1,227 among all predictions) |
| Evidence Level | L5 |
| EU Market Status | ✗ Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Fosaprepitant is the water-soluble intravenous prodrug of aprepitant, an NK1 (Substance P) receptor antagonist. Its established clinical use is antiemetic — blocking Substance P/NK1 signaling to suppress chemotherapy-induced nausea and vomiting, as reflected in the multiple oncology antiemetic trials associated with this drug in the evidence pack.
NSIAD, however, is a distinct rare genetic disorder caused by gain-of-function mutations in the AVPR2 (vasopressin V2) receptor, leading to inappropriate water retention independent of vasopressin levels. There is currently no known mechanistic link between NK1/Substance P receptor antagonism and AVPR2 receptor signaling. The evidence pack itself states explicitly: “此為 AVPR2 受體功能獲得性突變導致之罕見疾病，與 NK1/Substance P 路徑無已知機轉關聯，亦無任何臨床或臨床前證據支持” (a rare disease driven by AVPR2 gain-of-function mutation, with no known mechanistic connection to the NK1/Substance P pathway, and no clinical or preclinical evidence).
In short, this ranks as a pure knowledge-graph statistical signal (TxGNN score) without biological plausibility or empirical support. It should be treated as hypothesis-generating only, not as a basis for further development.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
Currently no related literature available
EU Market Information
Fosaprepitant currently has no marketing authorization on file in this jurisdiction (0 licenses; market status: not marketed).
Safety Considerations
Please refer to the SmPC for safety information.
(Key warnings, contraindications, and drug-interaction data were queried but not found in TFDA/DrugBank sources at this time — this is flagged as a blocking data gap (DG001) for any future safety evaluation of this drug.)
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked predicted indication (NSIAD) has no clinical trials, no literature, and no established mechanistic rationale — it is an L5, model-prediction-only signal with an explicit absence of biological plausibility. This does not meet the threshold to advance beyond S0.
To proceed, the following is needed:
- TFDA/regional label warnings and contraindications (currently a blocking data gap, DG001)
- Confirmed mechanism of action data for fosaprepitant (currently a high-severity data gap, DG002)
- If pursuing repurposing for this drug at all, consider re-screening lower-score candidates with actual mechanistic support instead — e.g., within this same evidence pack, retinitis (rank 7) has L4 preclinical evidence (PMID 32058829) showing fosaprepitant blocks UVR-induced NK1 receptor expression in ocular tissue, which is a more biologically grounded starting point than NSIAD
- Note: the multiple endocrine neoplasia (rank 5) candidate should also be disregarded — its cited trials are CINV antiemetic-support studies in oncology patients, not treatment trials for MEN itself, and are flagged in the pack as a likely co-occurrence false positive
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.